Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
SOBIV | Stockholm | SEK | Real-time | |
SOBIs | BATS Europe | SEK | Delayed | |
0MTD | London | SEK | Real-time |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Stefan Del Prato | - | - | Member of Scientific Advisory Board |
Jonathan Robert Sanders Arch | - | - | Member of Scientific Advisory Board |
Ralf Pettersson | - | - | Member of Scientific Advisory Board |
Stephen O'Rahilly | - | - | Member of Scientific Advisory Board |
Anders Ullman | 67 | 2023 | Director |
Hans Wigzell | 85 | 2001 | Chairman of Scientific Advisory Board |
Helena Saxon | 53 | 2011 | Director |
Annette V. Clancy | 70 | 2014 | Independent Chairman |
Christophe Bourdon | 54 | 2023 | Independent Director |
Katy Mazibuko | 51 | 2019 | Employee Representative Director |
Staffan Schuberg | 55 | 2020 | Independent Director |
Filippa Stenberg | 39 | 2021 | Director |
Mats Lek | 41 | 2023 | Employee Representative Director |
Sara Carlsson | 42 | 2023 | Deputy Employee Representative Director |
Asa Kjellstrom | 62 | 2023 | Deputy Employee Representative Director |
Zlatko Rihter | 54 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review